2025 article

GLOBAL PHASE II STUDY OF RISOVALISIB, A SELECTIVE PI3Kα INHIBITOR, AS MONOTHERAPY IN PATIENTS WITH RECURRENT/PERSISTENT OVARIAN CLEAR CELL CARCINOMA HARBORING PIK3CA HOTSPOT MUTATIONS

Xiaohua Wu, Kan Yonemori, Kaoru Niimi, Satoshi Nakagawa, Jiajia Li, Jihong Liu, Kosuke Yoshihara, Shogo Shigeta, Jianqing Zhu, Hui Qiu, Jie Tang, Hidemichi Watari, Tatsuyuki Chiyoda, Shoji Nagao, Liang ZhiQing, Yuanguang Meng, Huimei Zhou, R. An, Aikou Okamoto, Shin Nishio, Kazuhiro Takehara, Junzo Hamanishi, Shuzhong Yao, Fengxia Xue, Ge Lou, Hongming Pan, Wenjun Cheng, Rutie Yin, Wei Duan, Muneaki Shimada

5Citations signalées — pas une note de qualité

40Institutions déclarées

3Pays d’affiliation déclarés

Résumé indisponible : les résultats de l’étude ne doivent pas être déduits depuis son seul titre.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: GLOBAL PHASE II STUDY OF RISOVALISIB, A SELECTIVE PI3Kα INHIBITOR, AS MONOTHERAPY IN PATIENTS WITH RECURRENT/PERSISTENT OVARIAN CLEAR CELL CARCINOMA HARBORING PIK3CA HOTSPOT MUTATIONS
Date Crossref: 01/11/2025
Éditeur: Elsevier BV
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Fudan University Shanghai Cancer Center National Cancer Centre Japan National Cancer Center National Cancer Center Hospital East Tokyo National Hospital Nagoya University Osaka University Hospital Sun Yat-sen University Sun Yat-sen University Cancer Center Niigata University Medical and Dental Hospital Tohoku University Hospital Zhejiang Cancer Hospital Hangzhou Cancer Hospital Wuhan University Zhongnan Hospital of Wuhan University Hunan Cancer Hospital Hokkaido University Keio University Okayama University Southwest General Health Center Southwest Hospital Chinese PLA General Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Peking Union Medical College Hospital First Affiliated Hospital of Xi'an Jiaotong University Jikei University School of Medicine Kurume University Shikoku Cancer Center Kyoto University Hospital The First Affiliated Hospital, Sun Yat-sen University Tianjin Medical University General Hospital Harbin Medical University Third Affiliated Hospital of Harbin Medical University Sir Run Run Shaw Hospital Zhejiang University Jiangsu Provincial Hospital of Traditional Chinese Medicine Sichuan University West China Second University Hospital of Sichuan University Beijing Obstetrics and Gynecology Hospital Tohoku University

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Cell death mechanisms and regulationPI3K/AKT/mTOR signaling in cancerNF-κB Signaling Pathways

Consulter la publication primaire DOI